Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Promising vaccine may provide long-lasting protection against malaria

15.08.2002


Researchers have developed a unique vaccine that destroys a deadly toxin produced by the parasite that causes malaria, which kills more than two million people each year. The vaccine appears extremely promising in animal studies, they say.



If the drug works in humans, it could become a more effective and longer lasting anti-malarial vaccine than those currently available, according to the researchers.

Details of the research will be presented next week (Aug. 21) in Boston at the 224th national meeting of the American Chemical Society, the world’s largest scientific society. The study will be published in the Aug. 15 issue of Nature.


"This research represents an exciting new approach to controlling malaria by blocking the toxin that is responsible for so many deaths," says Peter H. Seeberger, Ph.D., associate professor of chemistry at the Massachusetts Institute of Technology in Cambridge, Mass. "We hope that this is the answer, but we don’t know yet."

Tests of the new vaccine in monkeys are slated to begin soon, while tests on humans could begin within two years, said Seeberger, who is co-leader of the study along with his colleague, Louis Schofield, Ph.D., of the Walter & Eliza Hall Institute of Medical Research in Melbourne, Australia.

Although other vaccines have been developed and tested against malaria, none lasts for more than a few weeks. Most target proteins on the surface of the parasite, which has the ability to change its surface proteins and eventually resist the vaccine, according to Seeberger.

The new vaccine targets the toxin instead of the parasite. Although the parasite itself lives, it is rendered harmless by the destruction of its deadly toxin, he said.

One or two shots of the vaccine are expected to provide lasting protection against the disease. If necessary, its effectiveness could be enhanced by using it in combination with other vaccines that target the malarial parasite, Seeberger said.

Malaria is a life-threatening parasitic disease transmitted by the bite of the female Anopheles mosquito, which transfers deadly one-celled parasites to human blood in an effort to nurture her eggs. The disease can be caused by one of four different parasites. The most lethal is Plasmodium falciparum, which is also responsible for the majority of infections.

Louis Schofield recently discovered that, as part of its life cycle inside its human host, the parasite releases an inflammatory toxin that appears to trigger the fever, convulsions and deaths associated with the disease.

Previous studies by Seeberger’s colleagues demonstrated that small amounts of the toxin — a tiny carbohydrate molecule called GPI — could be used to effectively immunize mice against infection and reduce fatalities. But the human immune system does not recognize such small molecules as foreign and cannot make antibodies to destroy them.

Seeberger and Schofield designed a synthetic version of the toxin and attached it to a protein molecule in hopes that the newly created complex would be large enough for the body to recognize so that an immune response could be launched against it.

When a group of healthy, unvaccinated mice were injected with blood containing a deadly malarial parasite, all died. But when the synthetic toxin was injected into a group of healthy mice and they were subsequently injected with the parasite, 65 to 95 percent survived.

The immunized mice also had enhanced protection from severe inflammatory conditions associated with the disease, including swelling of the brain, the researchers found.

Seeberger and his colleagues are continuing to refine their vaccine formulations to achieve a 100 percent survival rate. They hope that similar results will be seen in people.

According to the World Health Organization (WHO), malaria is one of the major public health problems, along with HIV/AIDS and tuberculosis, in the poorest regions of the world. More than 90 percent of deaths from malaria occur in Africa, mostly among infants and young children. It is estimated that the disease kills one African child every 30 seconds.

More recently, a dramatic surge in the number of malaria cases occurring among U.S. travelers to areas where the disease is common has been reported.


Funding for this research was provided by the National Institutes of Health, the United Nations Development Programme/World Bank/WHO Special Program for Research and Training in Tropical Diseases, the Human Frontiers of Science Program, the Howard Hughes Medical Institute, and the Australian National Health & Medical Research Council.

The paper on this research, CARB 81, will be presented at 9:25 a.m., Wednesday, Aug. 21, at Sheraton Boston, Republic B, during the symposium, "Carbohydrate Immunology and Therapeutics."

Peter H. Seeberger, Ph.D., is an associate professor of chemistry in the department of chemistry at Massachusetts Institute of Technology in Cambridge, Mass.

Louis Schofield, Ph.D., is a researcher at the Walter & Eliza Hall Institute of Medical Research in Melbourne, Australia.


Mark T. Sampson

Beverly Hassell | EurekAlert!
Further information:
http://www.acs.org/

More articles from Health and Medicine:

nachricht Hot cars can hit deadly temperatures in as little as one hour
24.05.2018 | Arizona State University

nachricht 3D images of cancer cells in the body: Medical physicists from Halle present new method
16.05.2018 | Martin-Luther-Universität Halle-Wittenberg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Powerful IT security for the car of the future – research alliance develops new approaches

The more electronics steer, accelerate and brake cars, the more important it is to protect them against cyber-attacks. That is why 15 partners from industry and academia will work together over the next three years on new approaches to IT security in self-driving cars. The joint project goes by the name Security For Connected, Autonomous Cars (SecForCARs) and has funding of €7.2 million from the German Federal Ministry of Education and Research. Infineon is leading the project.

Vehicles already offer diverse communication interfaces and more and more automated functions, such as distance and lane-keeping assist systems. At the same...

Im Focus: Molecular switch will facilitate the development of pioneering electro-optical devices

A research team led by physicists at the Technical University of Munich (TUM) has developed molecular nanoswitches that can be toggled between two structurally different states using an applied voltage. They can serve as the basis for a pioneering class of devices that could replace silicon-based components with organic molecules.

The development of new electronic technologies drives the incessant reduction of functional component sizes. In the context of an international collaborative...

Im Focus: LZH showcases laser material processing of tomorrow at the LASYS 2018

At the LASYS 2018, from June 5th to 7th, the Laser Zentrum Hannover e.V. (LZH) will be showcasing processes for the laser material processing of tomorrow in hall 4 at stand 4E75. With blown bomb shells the LZH will present first results of a research project on civil security.

At this year's LASYS, the LZH will exhibit light-based processes such as cutting, welding, ablation and structuring as well as additive manufacturing for...

Im Focus: Self-illuminating pixels for a new display generation

There are videos on the internet that can make one marvel at technology. For example, a smartphone is casually bent around the arm or a thin-film display is rolled in all directions and with almost every diameter. From the user's point of view, this looks fantastic. From a professional point of view, however, the question arises: Is that already possible?

At Display Week 2018, scientists from the Fraunhofer Institute for Applied Polymer Research IAP will be demonstrating today’s technological possibilities and...

Im Focus: Explanation for puzzling quantum oscillations has been found

So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics

Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

In focus: Climate adapted plants

25.05.2018 | Event News

Save the date: Forum European Neuroscience – 07-11 July 2018 in Berlin, Germany

02.05.2018 | Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

 
Latest News

In focus: Climate adapted plants

25.05.2018 | Event News

Flow probes from the 3D printer

25.05.2018 | Machine Engineering

Less is more? Gene switch for healthy aging found

25.05.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>